医学
肿瘤科
化疗
回顾性队列研究
内科学
中心（范畴论）
结晶学
化学
作者
L. Wu,Xiang-Shu Pu,L.B. Chen,Z.Q. Wang,Y.L. Liu,K. Li,Y. Kong,F. Xu,J. Li,L. Xu,Y. Xu,C.Y. Tang,LENA XIAO,P. Liu
标识
DOI：10.1016/j.jtho.2022.07.667
摘要
Recombinant human endostatin (Endostar) and Camrelizumab have been approved for NSCLC treatment combining with chemotherapy in China. This study aimed to investigate the efficacy and safety of combining Endostar with Camrelizumab plus chemotherapy in patients with advanced NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
Nole
Kao
cdercder
东方元语
123
OK
aajhajkahna
xing_xing
贪玩的秋柔
心态好
Criminology34
小何
学术文献互助
科研狗
cat
aaaa
GingerF
张欢馨
七听
pluto
皖公网安备34019202002308
